menu

Advances in Immunotherapy for Unresectable Stage III NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advances in Immunotherapy for Unresectable Stage III NSCLC   

9 of 10 episodes
1.00 credits
MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Program Post-Test
Program Post-Test Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Host: 
    Joshua E. Reuss, MD
    Assistant Professor of Medicine
    Georgetown University
    Washington, DC 

    Dr. Reuss has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Exelixis, Genentech/Roche, Nuvalent, Verastem 
    Consulting Fees: AbbVie, Arcus, AstraZeneca, BMS, CatalYm, Daiichi Sankyo, Gilead, Guardant, Janssen, Merck, Novocure, Personalis, Regeneron, Sanofi/Genzyme, Seagen, Summit Therapeutics 

    Faculty: 
    Jhanelle E. Gray, MD
    Department Chair, Thoracic Oncology
    Moffitt Cancer Center 
    Tampa, FL 

    Dr. Gray has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Research: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EMD Serono/Merck KGaA, G1 Therapeutics, Genentech, Gilead Sciences, Ludwig Institute of Cancer Research, Merck & Co, Novartis, Panbela Therapeutics, Pfizer, Regeneron 
    Consulting Fees: AbbVie, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, EMD Serono/Merck KGaA, Gilead Sciences, IDEOlogy Health, Janssen Scientific Affairs, Jazz Pharmaceuticals, Loxo Oncology, Merck & Co, Novartis, OncoCyte Biotechnology, Panbela Therapeutics, Regeneron, Spectrum ODAC, Takeda Pharmaceuticals, Triptych Health Partners 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose. 
    • Ann Early has nothing to disclose. 
    • Wilma Guerra has nothing to disclose. 
    • Amanda Holinka has nothing to disclose. 
    • Samantha Keehn has nothing to disclose. 
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:  

    • Implement the latest guideline recommendations and scientific evidence for the evaluation and staging of patients with suspected stage III non-small cell lung cancer (NSCLC)  
    • Incorporate the latest clinical and real-world evidence regarding the role of current and emerging immunotherapy approaches in unresectable stage III NSCLC  
    • Recognize differences between chemoradiotherapy and immunotherapy in terms of safety profile and toxicity management  
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and radiation oncologists who are involved in the management of patients with NSCLC. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.  This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until May 14, 2025. PAs should claim only the credit commensurate with the extent of their participation in the   activity.  


    Global Learning Collaborative (GLC) designates this activity for 1.00 contact hour/0.10 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-054-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).    

  • Provider(s)/Educational Partner(s)


    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by an independent educational grant from AstraZeneca. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.

Facebook Comments

Schedule20 May 2024